{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:33:02Z","timestamp":1791340382632,"version":"4.3.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Vifor Fresenius Medical Care Renal Pharma"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Renin\u2013angiotensin\u2013aldosterone system inhibitors (RAASi) are now a standard treatment in most patients with cardiovascular disease, especially in those with heart failure (HF). The European Society of Cardiology and the American College of Cardiology\/American Heart Association gave a Class IA recommendation for the use of RAASi in the treatment of Classes II\u2013IV symptomatic HF with reduced ejection fraction (HFREF), based on their strong clinical benefits of lowering all-cause mortality and HF hospitalizations in these subjects. However, RAASi therapy or adding mineralocorticoid receptor antagonists in subjects receiving background angiotensin-converting enzyme inhibitors or angiotensin receptor blockers may be associated with an increased risk of hyperkalemia (HK), especially in those with reduced kidney function. As a result, a significant proportion of these subjects either have RAASi dose reduced or more often discontinued when they develop HK. Discontinuation of RAASi in patients hospitalized with HFREF was associated with higher postdischarge mortality and rehospitalization rates, while optimal dosing of RAASi significantly reduced median hospital stays, outpatient visits and related costs. Thus, effective treatment is required to lower potassium level and maintain normokalemia in subjects with HF and reduced kidney disease who develop or are at risk of HK, thus enabling them to continue their RAASi therapy and maximize benefits from RAASi. In this review, we provide an up-to-date review of the prevalence and significance of HK in patients with cardiorenal syndrome, as well as their optimal management of HK with recent novel therapies.<\/jats:p>","DOI":"10.1093\/ndt\/gfz225","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T15:13:39Z","timestamp":1572966819000},"page":"iii36-iii44","source":"Crossref","is-referenced-by-count":17,"title":["Optimally managing hyperkalemia in patients with cardiorenal syndrome"],"prefix":"10.1093","volume":"34","author":[{"given":"Angela Yee-Moon","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"key":"2019120409205615000_gfz225-B1","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1186\/cc11872","article-title":"Severe hyperkalemia requiring hospitalization: predictors of mortality","volume":"16","author":"An","year":"2012","journal-title":"Crit Care"},{"key":"2019120409205615000_gfz225-B2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2019120409205615000_gfz225-B3","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","article-title":"Predictors of hyperkalemia and death in patients with cardiac and renal disease","volume":"109","author":"Jain","year":"2012","journal-title":"Am J Cardiol"},{"key":"2019120409205615000_gfz225-B4","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the heart failure society of America","volume":"23","author":"Yancy","year":"2017","journal-title":"J Card Fail"},{"key":"2019120409205615000_gfz225-B5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.amjcard.2014.12.045","article-title":"Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial)","volume":"115","author":"Khan","year":"2015","journal-title":"Am J Cardiol"},{"key":"2019120409205615000_gfz225-B6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ehf2.12402","article-title":"Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21334 patients in the UK","volume":"6","author":"Linde","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2019120409205615000_gfz225-B7","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","article-title":"Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program","volume":"50","author":"Desai","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2019120409205615000_gfz225-B8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2019120409205615000_gfz225-B9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2019120409205615000_gfz225-B10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2019120409205615000_gfz225-B11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2019120409205615000_gfz225-B12","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2019120409205615000_gfz225-B13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.510","article-title":"Physicians\u2019 adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey","volume":"18","author":"Komajda","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2019120409205615000_gfz225-B14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/pds.3748","article-title":"Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor\/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort","volume":"24","author":"Abbas","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2019120409205615000_gfz225-B15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1056\/NEJMra1313341","article-title":"An integrated view of potassium homeostasis","volume":"373","author":"Gumz","year":"2015","journal-title":"N Engl J Med"},{"key":"2019120409205615000_gfz225-B16","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/eurheartj\/ehy100","article-title":"Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis","volume":"39","author":"Kovesdy","year":"2018","journal-title":"Eur Heart J"},{"key":"2019120409205615000_gfz225-B17","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"key":"2019120409205615000_gfz225-B18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ekir.2017.11.003","article-title":"The cost of hyperkalemia in the United States","volume":"3","author":"Betts","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2019120409205615000_gfz225-B19","first-page":"S2","article-title":"Clinical and economic impact of hyperkalemia in patients with chronic kidney disease and heart failure","volume":"23","author":"Polson","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2019120409205615000_gfz225-B20","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1080\/13696998.2018.1518239","article-title":"Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure","volume":"21","author":"Bakhai","year":"2018","journal-title":"J Med Econ"},{"key":"2019120409205615000_gfz225-B21","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2019120409205615000_gfz225-B22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"2019120409205615000_gfz225-B23","first-page":"IV1","article-title":"2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care","volume":"112","year":"2005","journal-title":"Circulation"},{"key":"2019120409205615000_gfz225-B24","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2215\/CJN.03640415","article-title":"Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD","volume":"10","author":"Lepage","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019120409205615000_gfz225-B25","doi-asserted-by":"crossref","first-page":"264.e9","DOI":"10.1016\/j.amjmed.2012.08.016","article-title":"Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review","volume":"126","author":"Harel","year":"2013","journal-title":"Am J Med"},{"key":"2019120409205615000_gfz225-B26","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1074248416629549","article-title":"Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia","volume":"21","author":"Li","year":"2016","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2019120409205615000_gfz225-B27","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2215\/CJN.01170216","article-title":"Effect of patiromer on urinary ion excretion in healthy adults","volume":"11","author":"Bushinsky","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019120409205615000_gfz225-B28","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/ki.2015.270","article-title":"Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia","volume":"88","author":"Bushinsky","year":"2015","journal-title":"Kidney Int"},{"key":"2019120409205615000_gfz225-B29","doi-asserted-by":"crossref","first-page":"e114686","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"Stavros","year":"2014","journal-title":"PLoS One"},{"key":"2019120409205615000_gfz225-B30","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ki.2014.382","article-title":"A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient","volume":"88","author":"Ash","year":"2015","journal-title":"Kidney Int"},{"key":"2019120409205615000_gfz225-B31","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2019120409205615000_gfz225-B32","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00392-014-0678-2","article-title":"Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF","volume":"103","author":"Tebbe","year":"2014","journal-title":"Clin Res Cardiol"},{"key":"2019120409205615000_gfz225-B33","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jacc.2013.10.050","article-title":"Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease","volume":"63","author":"Molnar","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2019120409205615000_gfz225-B34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ejhf.1079","article-title":"Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF","volume":"20","author":"Beusekamp","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2019120409205615000_gfz225-B35","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2019120409205615000_gfz225-B36","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"2019120409205615000_gfz225-B37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ehf2.12265","article-title":"Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease","volume":"5","author":"Pitt","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2019120409205615000_gfz225-B38","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ehf2.12292","article-title":"Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes\/angiotensin receptor blockers: results from AMETHYST-DN","volume":"5","author":"Pitt","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2019120409205615000_gfz225-B39","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2019120409205615000_gfz225-B40","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"2019120409205615000_gfz225-B41","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s40273-018-0709-3","article-title":"Cost-effectiveness analysis of patiromer and spironolactone therapy in heart failure patients with hyperkalemia","volume":"36","author":"Bounthavong","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"2019120409205615000_gfz225-B42","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2019120409205615000_gfz225-B43","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.kint.2016.04.019","article-title":"Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors","volume":"90","author":"Weir","year":"2016","journal-title":"Kidney Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/Supplement_3\/iii36\/31200125\/gfz225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/Supplement_3\/iii36\/31200125\/gfz225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T09:26:12Z","timestamp":1575451572000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/34\/Supplement_3\/iii36\/5652178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":43,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2019,12,4]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfz225","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,12,1]]}}}